FULC Q4 2023 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$871,000+27.2% YoY

Gross Profit

$363,00041.7% margin

Operating Income

-$28M-3213.8% margin

Net Income

-$25M-2842.3% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+14.8%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$258M

Total Liabilities

$23M

Stockholders' Equity

$235M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$871,000	$685,000	+27.2%
Gross Profit	$363,000	-$18M	+102.0%
Operating Income	-$28M	-$28M	-0.1%
Net Income	-$25M	-$26M	+5.3%